In this Issue
- atai Sells a Third of Compass Stake to Raise Cash for In-House Programs
- Lykos’ Unproven Psychotherapy Hampered Studies, Claim Authors of New Viewpoint
- Picking Placebos for Psychedelic Studies
- Small Study of Psilocybin in Severe TRD Among Veterans Shows Promise, But Authors Encourage Tempering Expectations
- More Headlines
***
atai Sells a Third of Compass Stake to Raise Cash for In-House Programs
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue